Exhibit 99.1


Oragenics Names Robert Zahradnik as President, CEO

ALACHUA, FL. - September 13, 2005--Oragenics, Inc. (AMEX:ONI ) today announced
that Robert Zahradnik has been named President, Chief Executive Officer. Dr.
Zahradnik had been the Acting President, Chief Executive Officer since July,
2005 when he replaced Mento A. Soponis, who had retired from the post.

Dr. Zahradnik, a co-founder of Oragenics, was a member of the company's Board of
Directors from November 1996 until July, 2005, when he resigned his Board seat
so that the Company could remain in compliance with SEC rules regarding the mix
of independent and inside directors. Prior to joining Oragenics as an employee
in July, Dr. Zahradnik spent his career with Johnson & Johnson (NYSE: JNJ) in
various R&D management positions, with Advanced Clinical Technologies as
chairman and CEO, and as partner and general manager at Pro-Dentec Therapeutics.

"At Oragenics, Dr. Zahradnik has continued to utilize his extensive experience
in strategic planning and project management to position the Company to meet its
short and long-term objectives and to build shareholder value," commented David
Gury, Chairman of the Board.

Paul Hassie, Oragenics Chief Financial Officer, added, "Dr. Zahradnik has shown
in his career that he understands the importance of building the strengths of an
organization. With Bob and our current senior staff, we believe we have a strong
Management team in place and are confident of continued progress."

Oragenics is focused on the acquisition and development of novel technologies
and products to address significant, unmet medical needs.

Oragenics' strategy is to license and develop products through human
proof-of-concept studies prior to partnering with major pharmaceutical,
biotechnology or healthcare product firms for advanced clinical development and
commercialization.

Oragenics is currently developing several products, which address potentially
major market opportunities as follows:

      o     SMaRT Replacement Therapy is a single, painless topical treatment
            that has the potential to offer life-long protection from most tooth
            decay. This product is in Phase I clinical trials.

      o     Probiora 3 Oral Probiotic is a daily consumer product that employs
            naturally occurring beneficial bacteria to promote dental and
            periodontal health.

      o     MU 1140 is a novel antibiotic with activity against essentially all
            Gram-positive bacteria including multidrug resistant Staphylococcus
            aureus and Enterococcus faecalis. MU 1140 has a number of other
            characteristics that suggest its potential use in the treatment of a
            variety of infectious diseases.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of
1995: This release includes forward-looking statements that reflect Oragenics'
current views with respect to future events and financial performance. These
forward-looking statements are based on management's beliefs and assumptions and
information currently available. The words "believe," "expect," "anticipate,"
"intend," "estimate," "project" and similar expressions that do not relate
solely to historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because they are
subject to a variety of risks, uncertainties, and other factors that could cause
actual results to differ materially from those expressed in any such
forward-looking statements. These factors include, but are not limited to (1)
the ability to successfully complete development and commercialization of
Oragenics' Replacement Therapy for prevention of tooth decay, novel antibiotic,
and probiotic product for oral health; (2) the ability to obtain substantial
additional funding; (3) the ability to develop and commercialize products before
competitors; (4) the ability to develop commercial products with the in-licensed
technology; and (5) other factors detailed from time to time in filings with the
Securities and Exchange Commission. We expressly disclaim any responsibility to
update forward-looking statements.


- -----------------------
Contact:
     Oragenics, Inc.
     Paul A. Hassie, 386-418-4018 X232
     www.oragenics.com
     -----------------
     or
     Investor Awareness, Inc.
     Tony Schor, 847-945-2222
     www.investorawareness.com
     -------------------------